Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III outpatient study of continuous subcutaneous glucagon infusion

Next Previous
Search
Trial Profile

Phase III outpatient study of continuous subcutaneous glucagon infusion

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 28 Nov 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glucagon (Primary)
  • Indications Congenital hyperinsulinism
  • Focus Therapeutic Use

Most Recent Events

  • 21 Nov 2019 Status changed from planning to withdrawn prior to enrolment, according to a Xeris Pharmaceuticals media release. The company has decided to not proceed with this planned study based on the challenging regulatory pathway coupled with the limited market opportunity. Instead, the Company will consider requests to make its liquid stable glucagon available for approved Expanded Access requests at no cost to eligible patients.
  • 09 May 2019 According to a Xeris Pharmaceuticals media release, the company expects to initiate this study in mid-2019.
  • 12 Mar 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top